Sacubitril Impurities

Sacubitril impurities refer to unintended chemical entities that may arise during the synthesis, manufacturing, or storage of the pharmaceutical drug sacubitril, which is used to treat heart failure.

per page
Impurity structure Parent Drug Name Name of Impurity Catalogue No. CAS No.
Sacubitril (2R,4R)-Isomer Sacubitril

Sacubitril (2R,4R)-Isomer

VE005968 766480-48-2
Sacubitril (2S,4S)-Isomer Sacubitril

Sacubitril (2S,4S)-Isomer

VE005967 149709-63-7
Sacubitril (3R,5S) Pyrrolidinone Impurity Sacubitril

Sacubitril (3R,5S) Pyrrolidinone Impurity

VE005969 1038924-70-7
Sacubitril (3S,5S)-Pyrrolidinone Sacubitril

Sacubitril (3S,5S)-Pyrrolidinone

VE009210 1038925-00-6
Sacubitril Acid Impurity Sacubitril

Sacubitril Acid Impurity

VL3730004 N/A
Sacubitril AHU-66 Sacubitril

Sacubitril AHU-66

VE009417 1426129-50-1
Sacubitril Desethyl Impurity Sacubitril

Sacubitril Desethyl Impurity

VE005973 149709-44-4
Sacubitril Impurity 17 Sacubitril

Sacubitril Impurity 17

VE0019265 2376611-98-0
Sacubitril Isopropyl Ester Impurity Sacubitril

Sacubitril Isopropyl Ester Impurity

VL3730003 N/A
Sacubitril Lactam Impurity Sacubitril

Sacubitril Lactam Impurity

VE0018431 1038925-22-2
Sacubitril Maleic Acid (E-Isomer) Sacubitril

Sacubitril Maleic Acid (E-Isomer)

VE0018430 N/A
Sacubitril Methyl ester Sacubitril

Sacubitril Methyl ester

VE005972 2408053-56-3
Sacubitril Pyrrolidinone Impurity Sacubitril

Sacubitril Pyrrolidinone Impurity

VL3730005 2101222-51-7
Sacubitril SBT Diastereomer Impurity Sacubitril

Sacubitril SBT Diastereomer Impurity

VL3730001 N/A
Sacubitril SBT Enantiomer Sacubitril

Sacubitril SBT Enantiomer

VL3730002 N/A
Sacubitril-(2R,4R)-Isomer Sacubitril


VE0010483 2259708-00-2
Sacubitril-D4 Sacubitril


DVE001410 1884269-07-1
Sacubutril impurity 11 Sacubitril

Sacubutril impurity 11

VE005971 1038924-71-8
Sacubutril impurity 9 Sacubitril

Sacubutril impurity 9

VE005970 149690-12-0
(2R,4S)-4-amino-2-methyl-5-(4-phenylphenyl)pentanoic acid Sacubitril

(2R,4S)-4-amino-2-methyl-5-(4-phenylphenyl)pentanoic acid

VE009679 1039307-95-3
(2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-(3-carboxypropanamido)-2-methylpentanoic acid Sacubitril

(2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-(3-carboxypropanamido)-2-methylpentanoic acid

VE009690 N/A
(2R,4S)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic Acid Sacubitril

(2R,4S)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic Acid

VE009680 1012341-50-2
(2R,4S)-5-biphenyl-4yl-4-(3-carboxy-acryloylamino)-2-methyl-pentonic acid ethyl ester Sacubitril

(2R,4S)-5-biphenyl-4yl-4-(3-carboxy-acryloylamino)-2-methyl-pentonic acid ethyl ester

VE0010786 N/A
(2R,4S)-ethyl 5-([1,1'-biphenyl]-4-yl)-4-amino-2-methylpentanoate Sacubitril

(2R,4S)-ethyl 5-([1,1'-biphenyl]-4-yl)-4-amino-2-methylpentanoate

VE0016600 N/A
(2S,4R)-5-([1,1'-Biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpentanoic Acid Sacubitril

(2S,4R)-5-([1,1'-Biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpentanoic Acid

VE0011292 1012341-54-6
(2S,4R)-Sacubitril Sacubitril


VE009208 761373-05-1
(3R,5S)-3-methyl-5-(biphenyl-4-yl)pyrrolidin-2-one Sacubitril


VE0010752 N/A
(E)-(R)-5-Biphenyl-4-yl-4-(3-carboxypropionylamino)-2-methyl-pent-2-enoic acid ethyl ester Sacubitril

(E)-(R)-5-Biphenyl-4-yl-4-(3-carboxypropionylamino)-2-methyl-pent-2-enoic acid ethyl ester

VE009773 N/A
(R,E)-5-([1,1-Biphenyl]-4-Yl)-4-((Tert-Butoxycarbonyl)Amino)-2-Methylpent-2-Enoic Acid Sacubitril

(R,E)-5-([1,1-Biphenyl]-4-Yl)-4-((Tert-Butoxycarbonyl)Amino)-2-Methylpent-2-Enoic Acid

VE0020270 1012341-48-8
(R)-2-(tert-butylamino)-3-(4-iodophenyl)propan-1-ol Sacubitril


VE0019634 N/A
2,5-Dioxopyrrolidine Sacubitril Sacubitril

2,5-Dioxopyrrolidine Sacubitril

VE009209 1038924-97-8
4-Iodo-D-Phenylalanine Sacubitril


VE0019633 62561-75-5

Sacubitril Related Compound

Sacubitril is the first medicine in a new family of pharmaceuticals known as angiotensin receptor neprilysin inhibitors (ARNI). The medicine is intended to be used to treat individuals with chronic heart failure with reduced ejection fraction (HFrEF) who are in NYHA class II, III, or IV.


  • “Valsartan and Sacubitril: MedlinePlus Drug Information.”, 2020,,to%20help%20control%20blood%20volume. Accessed 8 Mar. 2023.
  • Iborra-Egea, Oriol, et al. “Mechanisms of Action of Sacubitril/Valsartan on Cardiac Remodeling: A Systems Biology Approach.” Npj Systems Biology and Applications, vol. 3, no. 1, Apr. 2017, Accessed 8 Mar. 2023.
  • “Caution Needed When Interpreting BNP in Sacubitril/Valsartan Treatment.” Mass General Advances in Motion, 3 Sept. 2020,,a%20slight%20subsequent%20downward%20trend. Accessed 8 Mar. 2023. ‌


What class of drug is sacubitril?

Sacubitril belongs to a class of drugs known as neprilysin inhibitors. It aids in the regulation of blood volume.

What is the mechanism of action of sacubitril?

Sacubitril, on the other hand, works by blocking the breakdown of endogenous vasoactive peptides such as natriuretic peptides (ANP, BNP, and CNP), hence decreasing myocardial cell death.

Does sacubitril increase BNP?

The beginning of sacubitril resulted in elevated BNP concentrations. The elevations were minor, with a little subsequent downward tendency.